Ashley Chan

Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.

The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Sacituzumab tirumotecan showed statistically significant improvements in responses and survival vs docetaxel alone in advanced EGFR-mutant NSCLC.

Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.

Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

The addition of pelabresib to ruxolitinib generated a significant improvement in spleen response in patients with JAK inhibitor–naive myelofibrosis.

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.